Tradestie Institutional Equity Comparison Engine

CRACU vs ACAD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin while CRACU counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRACU trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ACAD at 15.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, CRACU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
CRACU N/M vs ACAD 15.8x Fwd P/E
Growth & Margin Winner ACAD
Op Margin N/A vs 10.2% ยท YoY N/A vs +22.8%
Momentum & Technical Winner CRACU
1Y +4.4% vs -25.9% ยท 52W Pos 65% vs 8%
Options & Structure Winner CRACU
UNCLASSIFIED (N/A IV) vs BREAKDOWN (6th %ile IV)
CRACU US Equity
CRACU
Institutional Equity
$10.45
+0.97% 1D
Market Cap N/A
1M Return +2.55%
1Y Return +4.4%
Forward P/E N/M
Unified AI Score
62.1 / 100 BUY
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$17.11
-2.73% 1D
Market Cap $3.0B
1M Return -15.76%
1Y Return -25.93%
Forward P/E 15.8x
Unified AI Score
44.8 / 100 HOLD
Tech 38.0 Fund 54.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRACU +4.4% ACAD -25.93% Spread: +24.34 pp (CRACU Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRACU TTM Op. Margin: N/A ACAD TTM Op. Margin: 10.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRACU vs ACAD. Trailing 12-month operating profitability (CRACU N/A vs ACAD 10.2%) and valuation multiples (CRACU N/M vs ACAD 15.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRACU (3) vs ACAD (7)
Institutional Metric CRACU ACAD Criterion Row Winner
Market Capitalization Scale N/A $3.0B Larger Scale ACAD
Trailing P/E Ratio Valuation N/M 8.3x Lower Multiple ACAD
Forward P/E Ratio Valuation N/M 15.8x Lower Multiple ACAD
Revenue Growth (YoY) Growth N/A +22.8% Higher Growth ACAD
Operating Margin (TTM) Profitability N/A 10.2% Higher Margin ACAD
Net Profit Margin Profitability N/A 30.1% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency N/A 31.4% Higher ROE ACAD
52-Week Range Position Momentum 65% ($10โ€“$11) 8% ($16โ€“$31) Stronger Trend CRACU
Beta / 30D Volatility Risk Regime N/A 0.15ฮฒ ยท 90% Vol Lower Realized Risk CRACU
Unified Institutional Score Composite Signal 62.1 / 100 (BUY) 44.8 / 100 (HOLD) Higher Composite CRACU

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRACU vs ACAD Buy Guide
CRACU UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CRACU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRACU nor ACAD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.